Uncategorized
Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed. The paper, The Molecular Determinants of Papillomavirus Capsid Binding to Tumor Cells, was publis
